Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket
11:20am, Monday, 26'th Sep 2022 Benzinga
Gainers
RedHill Biopharma Ltd. (NASDAQ: RDHL) rose 31.4% to $0.6525 in pre-market trading after dipping over 20% on Friday. The European Commission, last month, granted Orphan Drug Designation to Red
Curis Announces Date for the 2nd Annual VISTA Symposium
09:16pm, Monday, 19'th Sep 2022
Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass.
Curis to Present at Upcoming Healthcare Conferences in September
08:00am, Wednesday, 07'th Sep 2022
LEXINGTON, Mass. , Sept. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
04:53pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
02:18pm, Wednesday, 31'st Aug 2022
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
04:25pm, Friday, 19'th Aug 2022 Zacks Investment Research
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
01:33pm, Friday, 19'th Aug 2022
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
07:54am, Friday, 19'th Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Plus Therapeutics, Inc. (NASDAQ: PSTV) shares climbed 53.9% to close at $0.8480
after the co
Dow Falls 60 Points; Crude Oil Rises Sharply
06:39pm, Thursday, 18'th Aug 2022 Benzinga
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 60 points on Thursday.
The Dow traded down 0.19% to 33,917.28 while the NASDAQ rose 0.24% to 12,968.90. The S&P a
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
04:54pm, Thursday, 18'th Aug 2022 Benzinga
Gainers
Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) shares rose 50.9% to $1.1299 amid mention of the stock on Discord. Mind
U.S. Stocks Turn Higher; Nasdaq Rises 50 Points
04:00pm, Thursday, 18'th Aug 2022 Benzinga
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining 50 points on Thursday.
The Dow traded up 0.02% to 33,988.56 while the NASDAQ rose 0.39% to 12,988.14. The S&P also r
Why Is Curis (CRIS) Stock Up 20% Today?
11:21am, Thursday, 18'th Aug 2022
Source: Gorodenkoff / Shutterstock.com Today is a big day for biotech firm Curis (NASDAQ: CRIS ) and CRIS stock. The U.S. Food and Drug Administration (FDA) just completed its review of the company's
Curis (CRIS) Q2 2022 Earnings Call Transcript
07:30am, Friday, 05'th Aug 2022 The Motley Fool
CRIS earnings call for the period ending June 30, 2022.
Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2022 Results - Earnings Call Transcript
04:42am, Friday, 05'th Aug 2022
Curis, Inc. (NASDAQ:CRIS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Craig West - VP, IR & Corporate Communications Jim Dentzer - President & CEO Bill Steinkrauss
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
10:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
